alprazolam has been researched along with Obesity in 4 studies
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, given its central inhibitory action on the HPA axis, we investigated whether the suppressive capacity of alprazolam (APZ) pretreatment on the hormone response to low-dose AVP challenge and daily urinary free cortisol (UFC) excretion rate may be altered in the presence of obesity." | 9.11 | Response of the hypothalamic-pituitary-adrenal axis to small dose arginine-vasopressin and daily urinary free cortisol before and after alprazolam pre-treatment differs in obesity. ( Ceroni, L; Gagliardi, L; Gambineri, A; Genghini, S; Pagotto, U; Pasquali, R; Vicennati, V, 2004) |
| " In addition, given its central inhibitory action on the HPA axis, we investigated whether the suppressive capacity of alprazolam (APZ) pretreatment on the hormone response to low-dose AVP challenge and daily urinary free cortisol (UFC) excretion rate may be altered in the presence of obesity." | 5.11 | Response of the hypothalamic-pituitary-adrenal axis to small dose arginine-vasopressin and daily urinary free cortisol before and after alprazolam pre-treatment differs in obesity. ( Ceroni, L; Gagliardi, L; Gambineri, A; Genghini, S; Pagotto, U; Pasquali, R; Vicennati, V, 2004) |
| "Alprazolam was a contributing cause of death in a substantial and increasing number of drug-related deaths." | 1.38 | Characteristics of alprazolam-related deaths compiled by a centralized state medical examiner. ( Abate, MA; Clay, DJ; Kaplan, JA; Kraner, JC; Shah, NA; Smith, MJ, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shah, NA | 1 |
| Abate, MA | 1 |
| Smith, MJ | 1 |
| Kaplan, JA | 1 |
| Kraner, JC | 1 |
| Clay, DJ | 1 |
| Vicennati, V | 1 |
| Ceroni, L | 1 |
| Gagliardi, L | 1 |
| Pagotto, U | 1 |
| Gambineri, A | 1 |
| Genghini, S | 1 |
| Pasquali, R | 1 |
| Grottoli, S | 2 |
| Arvat, E | 2 |
| Gauna, C | 2 |
| Maccagno, B | 2 |
| Ramunni, J | 2 |
| Giordano, R | 2 |
| Maccario, M | 2 |
| Deghenghi, R | 2 |
| Ghigo, E | 2 |
2 trials available for alprazolam and Obesity
| Article | Year |
|---|---|
Response of the hypothalamic-pituitary-adrenal axis to small dose arginine-vasopressin and daily urinary free cortisol before and after alprazolam pre-treatment differs in obesity.
Topics: Adult; Alprazolam; Arginine Vasopressin; Dose-Response Relationship, Drug; Female; GABA Modulators; | 2004 |
Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.
Topics: Adrenocorticotropic Hormone; Adult; Alprazolam; Anti-Anxiety Agents; Corticotropin-Releasing Hormone | 1999 |
2 other studies available for alprazolam and Obesity
| Article | Year |
|---|---|
Characteristics of alprazolam-related deaths compiled by a centralized state medical examiner.
Topics: Adult; Alprazolam; Analgesics, Opioid; Cardiovascular Diseases; Cause of Death; Comorbidity; Drug Ov | 2012 |
Alprazolam, a benzodiazepine, blunts but does not abolish the ACTH and cortisol response to hexarelin, a GHRP, in obese patients.
Topics: Adrenocorticotropic Hormone; Adult; Alprazolam; Female; GABA Modulators; Growth Substances; Humans; | 2000 |